scholarly journals mTOR inhibition improves mitochondria function/biogenesis and delays cardiovascular aging in kidney transplant recipients with chronic graft dysfunction

Aging ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 8026-8039
Author(s):  
Barbara Infante ◽  
Francesco Bellanti ◽  
Michele Correale ◽  
Paola Pontrelli ◽  
Rossana Franzin ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Transplant Recipients ◽  
Graft Dysfunction ◽  
Kidney Transplant Recipients ◽  
Mtor Inhibition ◽  
Chronic Graft Dysfunction ◽  
Cardiovascular Aging

Association of Factor V Leiden Mutation with Delayed Graft Function, Acute Rejection Episodes and Long-term Graft Dysfunction in Kidney Transplant Recipients

2002 ◽  
Vol 87 (02) ◽  
pp. 194-198 ◽  
Author(s):  
Torsten Slowinski ◽  
Ingeborg Hauser ◽  
Birgit Vetter ◽  
Lutz Fritsche ◽  
Daniela Bachert ◽  
...  
Keyword(s):  
Acute Rejection ◽  
Kidney Transplant ◽  
Graft Function ◽  
Factor V Leiden ◽  
Factor V ◽  
Transplant Recipients ◽  
Graft Dysfunction ◽  
Kidney Transplant Recipients ◽  
Factor V Leiden Mutation

SummaryWe analysed whether the factor V Leiden mutation – the most common hereditary predisposing factor for venous thrombosis – is associated with early and long-term graft dysfunction after kidney transplantation in 394 Caucasian kidney transplant recipients. The presence of factor V Leiden mutation was identified by allele specific PCR. The prevalence of the factor V Leiden mutation was compared to 32216 unselected neonates. The prevalence of the factor V Leiden mutation (GA genotype) was similar in 394 kidney transplant recipients and 32216 neonates. The frequency of known factors predicting long-term graft function were similar in patients with the GA genotype and with the normal factor V gene (GG genotype). The GA genotype was associated with the occurrence of no primary graft function (risk: 2.87; 95% confidence interval: 1.01-8.26; p < 0.05), the number of dialysis after transplantation in patients with no primary graft function until graft function (7.5 ± 2.06 dialysis in GA patients; 4.2 ± 0.36 dialyses in GG patients; p < 0.05), and the risk for at least one acute rejection episode (risk: 3.83; 95% confidence interval: 1.38-10.59; p < 0.02). The slope of 1/creatinine per year was significantly lower in patients with the GA genotype (GA patients: – 0.0204 ± 0.008 dl/mg per year; GG patients: 0.0104 ± 0.004 dl/mg per year; p < 0.02). The annual enhancement of the daily protein excretion rate was elevated in patients with the GA genotype (GA patients: 38.5 ± 16.6 mg/24 h per year; GG patients: 4.9 ± 4.4 mg/24 h per year; p < 0.02). Our study showed that the factor V Leiden mutation is associated with the occurrence of delayed graft function, acute rejection episodes and chronic graft dysfunction after kidney transplantation.

scholarly journals Graft dysfunction and tacrolimus nephrotoxicity in kidney transplant recipients

2016 ◽  
Vol 10 (4) ◽  
pp. 83
Author(s):  
Karan Saraf ◽  
Ravindra Prabhu ◽  
Shankar Prasad ◽  
R. Dharshan ◽  
Srikanth Prasad ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Transplant Recipients ◽  
Graft Dysfunction ◽  
Kidney Transplant Recipients

392: Predictors of early postpartum graft dysfunction in kidney transplant recipients

2008 ◽  
Vol 199 (6) ◽  
pp. S119
Author(s):  
Jolene Seibel-Seamon ◽  
Benjamin Leiby ◽  
Serban Constantinescu ◽  
Michael Moritz ◽  
Vincenzo Berghella ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Transplant Recipients ◽  
Graft Dysfunction ◽  
Kidney Transplant Recipients ◽  
Early Postpartum

mTOR inhibition in kidney transplant recipients

2011 ◽  
Vol 7 (10) ◽  
pp. 553-555 ◽  
Author(s):  
Sarah E. Yost ◽  
Rochelle Byrne ◽  
Bruce Kaplan
Keyword(s):  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Mtor Inhibition

scholarly journals mTOR-Inhibition and COVID-19 in Kidney Transplant Recipients: Focus on Pulmonary Fibrosis

2021 ◽  
Vol 12 ◽  
Author(s):  
Simona Granata ◽  
Pierluigi Carratù ◽  
Giovanni Stallone ◽  
Gianluigi Zaza
Keyword(s):  
Pulmonary Fibrosis ◽  
Kidney Transplant ◽  
Therapeutic Potential ◽  
Severe Disease ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Mtor Inhibition ◽  
Pharmacological Interaction ◽  
Risk Of Progression ◽  
Growth Activity

Kidney transplant recipients are at high risk of developing severe COVID-19 due to the coexistence of several transplant-related comorbidities (e.g., cardiovascular disease, diabetes) and chronic immunosuppression. As a consequence, a large part of SARS-CoV-2 infected patients have been managed with a reduction of immunosuppression. The mTOR-I, together with antimetabolites, have been often discontinued in order to minimize the risk of pulmonary toxicity and to antagonize pharmacological interaction with antiviral/anti-inflammatory drugs. However, at our opinion, this therapeutic strategy, although justified in kidney transplant recipients with severe COVID-19, should be carefully evaluated in asymptomatic/paucisymptomatic patients in order to avoid the onset of acute allograft rejections, to potentially exploit the mTOR-I antiviral properties, to reduce proliferation of conventional T lymphocytes (which could mitigate the cytokine storm) and to preserve Treg growth/activity which could reduce the risk of progression to severe disease. In this review, we discuss the current literature regarding the therapeutic potential of mTOR-Is in kidney transplant recipients with COVID-19 with a focus on pulmonary fibrosis.

Kidney graft function before pregnancy as a predictor of graft, maternal and fetal outcomes in pregnant renal transplant recipients

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Filipe S. Mira ◽  
Joana Oliveira ◽  
Filipa Sousa ◽  
Dora Antunes ◽  
Ana Carolina Figueiredo ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Graft Function ◽  
Adverse Outcomes ◽  
Hypertensive Disorder ◽  
Renal Transplant Recipients ◽  
Kidney Graft ◽  
Transplant Recipients ◽  
Graft Dysfunction ◽  
Kidney Transplant Recipients

Abstract Objectives Maternal and fetal complications can occur in pregnant kidney transplant recipients. Since these are high-risk pregnancies, they require a multidisciplinary follow-up to prematurely detect adverse events. Identifying factors that would affect fetal, maternal and graft outcomes is essential to further stratify the risk of pregnant kidney transplant recipients. Methods All pregnancies in kidney transplant recipients followed in a single center for 30 years were included. Data included previous transplant information and blood and urine tests performed before pregnancy. Impact of graft function on fetal, maternal and graft outcomes was evaluated. Results There were 41 pregnancies among 34 patients. Mean gestational age of 35 ± 3 weeks. Caesarean section was performed in 69.4% of patients. Five pregnancies were unsuccessful (12.2%). Four patients suffered an acute graft dysfunction (9.8%) and 12 (29.3%) had a serious maternal hypertensive disorder (preeclampsia, eclampsia or HELLP syndrome). Graft function before pregnancy showed significant correlation with adverse outcomes. Conclusions A proteinuria >669 mg/g, serum creatinine >1.75 mg/dL and glomerular filtration rate <36.2 mL/min/1.73 m2 before pregnancy were correlated to graft dysfunction during pregnancy. Similar values of proteinuria were also associated with a risk of maternal hypertensive disorders and pregnancy failure. Therefore, in patients with proteinuria and graft dysfunction, follow-up should be stricter to quickly detect complications.

Micro RNA142-3p Is Differentially Expressed in the Peripheral Blood of Kidney Transplant Recipients With Graft Dysfunction Without Acute Rejection.

2014 ◽  
Vol 98 ◽  
pp. 464
Author(s):  
T. Domenico ◽  
G. Joelsons ◽  
F. Spuldaro ◽  
R. Montenegro ◽  
L. Goncalves ◽  
...  
Keyword(s):  
Acute Rejection ◽  
Kidney Transplant ◽  
Peripheral Blood ◽  
Differentially Expressed ◽  
Transplant Recipients ◽  
Graft Dysfunction ◽  
Kidney Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document